Esperion Therapeutics Stock Total Asset
| ESPR Stock | USD 2.97 0.13 4.58% |
Fundamental analysis of Esperion Therapeutics allows traders to better anticipate movements in Esperion Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
| Last Reported | Projected for Next Year | ||
| Total Assets | 343.8 M | 192.8 M |
Esperion | Total Asset | Build AI portfolio with Esperion Stock |
Esperion Therapeutics Company Total Asset Analysis
Esperion Therapeutics' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Esperion Therapeutics Total Asset | 343.82 M |
Most of Esperion Therapeutics' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Esperion Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Esperion Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Esperion Therapeutics is extremely important. It helps to project a fair market value of Esperion Stock properly, considering its historical fundamentals such as Total Asset. Since Esperion Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Esperion Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Esperion Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Esperion Total Assets
Total Assets |
|
Based on the latest financial disclosure, Esperion Therapeutics has a Total Asset of 343.82 M. This is 95.43% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The total asset for all United States stocks is 98.83% higher than that of the company.
Esperion Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Esperion Therapeutics' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Esperion Therapeutics could also be used in its relative valuation, which is a method of valuing Esperion Therapeutics by comparing valuation metrics of similar companies.Esperion Therapeutics is currently under evaluation in total asset category among its peers.
Esperion Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Esperion Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Esperion Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Esperion Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Esperion Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Esperion Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Esperion Therapeutics' value.| Shares | Two Sigma Investments Llc | 2025-06-30 | 1.8 M | Northern Trust Corp | 2025-06-30 | 1.8 M | Ubs Group Ag | 2025-06-30 | 1.5 M | Woodline Partners Lp | 2025-06-30 | 1.5 M | Royal Bank Of Canada | 2025-06-30 | 1.2 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 1.1 M | Susquehanna International Group, Llp | 2025-06-30 | 836.5 K | Bank Of America Corp | 2025-06-30 | 836.3 K | Goldman Sachs Group Inc | 2025-06-30 | 798.8 K | Blackrock Inc | 2025-06-30 | 14.7 M | Vanguard Group Inc | 2025-06-30 | 11.7 M |
Esperion Fundamentals
| Return On Equity | -2.61 | ||||
| Return On Asset | -0.0634 | ||||
| Profit Margin | (0.39) % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 800.91 M | ||||
| Shares Outstanding | 231.62 M | ||||
| Shares Owned By Insiders | 0.45 % | ||||
| Shares Owned By Institutions | 45.47 % | ||||
| Number Of Shares Shorted | 24.42 M | ||||
| Price To Earning | (8.19) X | ||||
| Price To Book | 98.42 X | ||||
| Price To Sales | 2.57 X | ||||
| Revenue | 332.31 M | ||||
| Gross Profit | 123.96 M | ||||
| EBITDA | 7.57 M | ||||
| Net Income | (51.74 M) | ||||
| Cash And Equivalents | 185.84 M | ||||
| Cash Per Share | 2.79 X | ||||
| Total Debt | 591.21 M | ||||
| Current Ratio | 3.07 X | ||||
| Book Value Per Share | (2.17) X | ||||
| Cash Flow From Operations | (23.65 M) | ||||
| Short Ratio | 2.90 X | ||||
| Earnings Per Share | (0.54) X | ||||
| Price To Earnings To Growth | (4.78) X | ||||
| Target Price | 6.09 | ||||
| Number Of Employees | 304 | ||||
| Beta | 0.96 | ||||
| Market Capitalization | 687.92 M | ||||
| Total Asset | 343.82 M | ||||
| Retained Earnings | (1.6 B) | ||||
| Working Capital | 91.77 M | ||||
| Current Asset | 214.39 M | ||||
| Current Liabilities | 5.62 M | ||||
| Net Asset | 343.82 M |
About Esperion Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Esperion Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Esperion Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Esperion Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Esperion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Esperion Stock
| 0.71 | RAC | Race Oncology | PairCorr |
| 0.72 | CMB | Cambium Bio | PairCorr |
| 0.87 | DMAC | DiaMedica Therapeutics Earnings Call This Week | PairCorr |
Moving against Esperion Stock
The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.
The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.